<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03097120</url>
  </required_header>
  <id_info>
    <org_study_id>U01HL45488</org_study_id>
    <nct_id>NCT03097120</nct_id>
  </id_info>
  <brief_title>The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.</brief_title>
  <acronym>ERA</acronym>
  <official_title>The Estrogen Replacement and Atherosclerosis Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Heart disease is a major cause of illness and death in women. To understand
      better the role of estrogen in the treatment and prevention of heart disease, more
      information is needed about its effects on coronary atherosclerosis and the extent to which
      concomitant progestin therapy may modify these effects.

      Methods: The investigators randomly assigned a total of 309 women with angiographically
      verified coronary disease to receive 0.625 mg of conjugated estrogen per day, 0.625 mg of
      conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate per day, or placebo. The women
      were followed for a mean (±SD) of 3.2±0.6 years. Base-line and follow-up coronary angiograms
      were were analyzed by quantitative methods. Follow-up coronary angiograms were obtained after
      an average of 3.2 years of follow up.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 1995</start_date>
  <completion_date type="Actual">January 2001</completion_date>
  <primary_completion_date type="Actual">January 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean minimal coronary-artery diameter</measure>
    <time_frame>at average of 3.2 years follow-up</time_frame>
    <description>mean minimal coronary-artery diameter within each subject at follow-up, analyzed on an intention-to-treat basis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>stenosis as a percentage of the reference diameter</measure>
    <time_frame>at average of 3.2 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>development of new lesions in a patient</measure>
    <time_frame>at average of 3.2 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Models focusing on change in diameter were also examined</measure>
    <time_frame>at average of 3.2 years follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">309</enrollment>
  <condition>Heart Disease</condition>
  <arm_group>
    <arm_group_label>unopposed estrogen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.625 mg of conjugated equine estrogen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>estrogen-plus-medroxyprogesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.625 mg of conjugated equine estrogen</intervention_name>
    <description>one tablet containing 0.625 mg of conjugated equine estrogen and a placebo tablet daily</description>
    <arm_group_label>unopposed estrogen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate</intervention_name>
    <description>one tablet of 0.625 mg of conjugated equine estrogen plus one tablet 2.5 mg of medroxyprogesterone acetate daily</description>
    <arm_group_label>estrogen-plus-medroxyprogesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo tablets</intervention_name>
    <description>two placebo tablets daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  postmenopausal

          -  not currently receiving estrogen-replacement treatment

          -  one or more epicardial coronary stenoses of at least 30 percent of the luminal
             diameter, as measured by quantitative coronary angiography

        Exclusion Criteria:

          -  known or suspected breast or endometrial carcinoma

          -  previous or planned coronary-artery bypass surgery,

          -  a history of deep-vein thrombosis or pulmonary embolism,

          -  symptomatic gallstones,

          -  serum aspartate aminotransferase level more than 1.5 times the normal value,

          -  fasting triglyceride level of more than 400 mg per deciliter

          -  serum creatinine level of more than 2.0 mg per deciliter

          -  more than 70 percent stenosis of the left main coronary artery,

          -  uncontrolled hypertension, or

          -  uncontrolled diabetes.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M. Herrington, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Herrington DM, Reboussin DM, Klein KP, Sharp PC, Shumaker SA, Snyder TE, Geisinger KR. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Control Clin Trials. 2000 Jun;21(3):257-85. Erratum in: Control Clin Trials 2000 Aug;21(4):414.</citation>
    <PMID>10822123</PMID>
  </reference>
  <results_reference>
    <citation>Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000 Aug 24;343(8):522-9.</citation>
    <PMID>10954759</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2011</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

